Conflict of interest statement: The authors declare no competing financialinterest.6. Ther Adv Med Oncol. 2018 Jul 11;10:1758835918782356. doi:10.1177/1758835918782356. eCollection 2018.Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ basedon hormone receptor status?Harbeck N(1).Author information: (1)Breast Center, University of Munich (LMU), Marchioninistrasse 15, Munich,81377, Germany.DOI: 10.1177/1758835918782356 PMCID: PMC6048618PMID: 30034548 